The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net earnings | 238,300 | 137,900 | 231,200 | 336,000 |
| Depreciation and amortization | 270,000 | 284,000 | 283,600 | 271,800 |
| Share-based compensation | 24,200 | 24,100 | 25,300 | 21,200 |
| Deferred income tax benefit | - | -87,200 | - | - |
| Income taxes | -7,400 | 8,100 | -42,700 | -116,400 |
| Receivables | -14,500 | 111,700 | -3,000 | -200 |
| Inventories | 20,900 | -184,400 | 46,000 | 37,200 |
| Accounts payable and accrued liabilities | -183,000 | 112,900 | -51,500 | 76,800 |
| Other assets and liabilities | -23,500 | 35,100 | -15,800 | -8,400 |
| Net cash provided by operating activities | 359,400 | 517,400 | 814,400 | 747,600 |
| Additions to instruments | 77,200 | 74,300 | 86,000 | 80,500 |
| Additions to other property, plant and equipment | 36,300 | 74,800 | 55,000 | 50,100 |
| Net investment hedge settlements | 300 | -4,900 | 8,800 | -2,500 |
| Business combination investments, net of acquired cash | - | 166,900 | 0 | 1,226,300 |
| Acquisition of intangible assets | 39,000 | 10,000 | 10,000 | 30,000 |
| Other investing activities | 6,200 | 800 | 3,500 | 0 |
| Net cash used in investing activities | -159,000 | -322,000 | -318,200 | -1,631,400 |
| Net proceeds from revolving facilities | - | - | - | 220,000 |
| Proceeds from senior notes | - | 0 | 744,000 | 0 |
| Redemption of senior notes | - | 600,000 | 0 | 0 |
| Dividends paid to stockholders | 46,900 | 47,500 | 47,500 | 47,500 |
| Proceeds from employee stock compensation plans | 12,300 | 1,700 | 20,900 | 400 |
| Business combination contingent consideration payments | 69,000 | 0 | 7,600 | 0 |
| Debt issuance costs | - | 0 | 5,400 | 1,200 |
| Repurchase of common stock | 250,100 | 250,000 | 0 | 7,200 |
| Other financing activities | -15,600 | -1,100 | -500 | -900 |
| Net cash (used in) provided by financing activities | -369,200 | -897,000 | 381,900 | 71,900 |
| Effect of exchange rates on cash and cash equivalents | 1,100 | 800 | -3,400 | 14,600 |
| Change in cash and cash equivalents | -167,700 | -700,800 | 735,800 | -827,700 |
| Cash and cash equivalents, beginning of year | 1,292,700 | - | 556,900 | 1,384,500 |
| Cash and cash equivalents, end of period | 424,200 | - | 1,292,700 | 556,900 |
ZIMMER BIOMET HOLDINGS, INC. (ZBH)
ZIMMER BIOMET HOLDINGS, INC. (ZBH)